The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer

Gynecologic Oncology - Tập 130 - Trang 377-382 - 2013
K.M. Moxley1, D.M. Benbrook1,2, L. Queimado3,4,5, R.E. Zuna6, D. Thompson7, M. McCumber7, P. Premkumar2, E. Thavathiru2, L. Hines2, K.N. Moore1
1Department of Obstetrics and Gynecology, College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
2Department of Biochemistry and Molecular Biology, College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
3Department of Otorhinolaryngology, College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
4Department of Cell Biology, College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
5Department of Pediatrics, College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
6Department of Pathology, College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
7College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Tài liệu tham khảo

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Trimbos, 2003, International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian carcinoma, J Natl Cancer Inst, 95, 105, 10.1093/jnci/95.2.113 Omura, 1986, A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study, Cancer, 57, 1725, 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J Omura, 1989, Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study, J Clin Oncol, 7, 457, 10.1200/JCO.1989.7.4.457 Aabo, 1998, (Advanced Ovarian Cancer Trialists' Group). Chemotherapy in advanced ovarian cancer: four systematic meta-analysis of individual patient data from 37 randomized trials, Br J Cancer, 78, 1479, 10.1038/bjc.1998.710 Markman, 1991, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J Clin Oncol, 9, 389, 10.1200/JCO.1991.9.3.389 Markman, 1992, Responses to “salvage” chemo-therapy in ovarian cancer: a critical need for precise definitions of the treated population, J Clin Oncol, 10, 513, 10.1200/JCO.1992.10.4.513 Braithwaite, 1999, Repair of DNA lesions: mechanisms and relative repair efficiencies, Mutat Res, 424, 207, 10.1016/S0027-5107(99)00020-2 Ferry, 2000, Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF, Biochem Pharmacol, 60, 1305, 10.1016/S0006-2952(00)00441-X Kirschner, 2010, Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs, Anticancer Res, 30, 3223 Hatfield, 2006, Identification of MMS19 domains with distinct functions in NER and transcription, DNA Repair (Amst), 5, 914, 10.1016/j.dnarep.2006.05.007 Olaussen, 2006, DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570 Bewick, 2011, Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer, J Cancer Res Clin Oncol, 137, 543, 10.1007/s00432-010-0915-7 Stoehlmacher, 2004, A multi-variate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer, Br J Can, 91, 344, 10.1038/sj.bjc.6601975 Gandara, 2010, Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer, J Thorac Oncol, 5, 1933, 10.1097/JTO.0b013e3181fd418d Darcy, 2007, A gynecologic oncology group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage IIIC epithelial ovarian cancer treated with platinum-taxane chemotherapy, Cancer Res, 67, 4474, 10.1158/0008-5472.CAN-06-4076 Steffensen, 2009, The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer, Int J Gynecol Cancer, 19, 820, 10.1111/IGC.0b013e3181a12e09 Miller, 1982, Genetic control of excision of Sacchromyces cerevisiae interstrand DNA cross-links induced by psoralen plus near-UV light, Mol Cell Biol, 2, 939, 10.1128/MCB.2.8.939 McWilliams, 2009, Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L, Can Epi Bio Prev, 8, 1295, 10.1158/1055-9965.EPI-08-1109 Zhang, 2012, Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy, PLoS One, 7, e48350, 10.1371/journal.pone.0048350 Krivak, 2008, Relationship between ERCC1 polymorphisms, disease progression and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer, J Clin Oncol, 26, 3598, 10.1200/JCO.2008.16.1323 Cannistra, 2007, Phase II study of bevacizumab in patient with platinum-resistant ovarian cancer of peritoneal, J Clin Oncol, 25, 822, 10.1200/JCO.2007.12.0782 Wang, 2011, Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma, Oncol Rep, 25, 52 NCI Steffensen, 2008, Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer, Int J Gynecol Cancer, 18, 702, 10.1111/j.1525-1438.2007.01068.x
Thông tin
Thông tin xuất bản

Gynecologic Oncology

Tập 130

377-382

Thông tin tác giả